Clinical Trial Update: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment [Phase 2]

View source ↗

Summary

Phase 2 study of BMS-790052 (daclatasvir) combined with pegylated interferon and ribavirin in patients who failed prior hepatitis C treatment has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-790052 (daclatasvir)
• Peginterferon (Pegylated interferon)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2015-10-12